Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
- Details
- Category: Clinical Trials
Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.
Three-year analysis demonstrates continued robust treatment effect of Alemtuzumab compared to Rebif
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, announced that top-line, three-year data from the CAMMS223 Phase II clinical trial comparing alemtuzumab with Rebif® (interferon beta-1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. The results come from an analysis conducted at 36 months following treatment of 334 patients in the three-year trial.
Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care
- Details
- Category: Pfizer
Pfizer Inc and Sermo, the nation's largest online physician community, today announced a strategic collaboration designed to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care. Sermo is a Web-based community where physicians share observations from daily practice, discuss emerging trends and provide new insights into medications, devices and treatments.
Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the third quarter of 2007 on Thursday, October 25. During a conference call on October 25 at 10:30 a.m. (ET), financial information will be reviewed and company executives will address inquiries from investors and analysts.
Boehringer Ingelheim distinguished as number one Top Employer 2007 by Science Magazine
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has been ranked first among the top employers in the pharmaceutical and biopharmaceutical industry according to the 2007 Top Employers survey conducted by Science. Science's annual survey polls employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries.
Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
- Details
- Category: Abbott
Abbott has been named to Hispanic Business magazine's list of the nation's best companies for Hispanics. Abbott was recognized as one of the magazine's "Diversity Elite 60" companies for its commitment to Hispanic hiring, promotion, marketing, philanthropy and supplier diversity.
Teva Announces Approval of Generic Actonel®
- Details
- Category: Product
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Procter and Gamble Actonel® (Risedronate Sodium) Tablets, 5 mg, 30 mg and 35 mg.
More Pharma News ...
- EPO Rules European Nexium® Process Patent Valid
- Aptivus® (tipranavir) capsules granted full approval by the U.S. FDA
- Aclasta® receives European approval as first once-yearly treatment for postmenopausal osteoporosis
- GSK seeks prequalification for Cervarix⢠from the World Health Organization
- Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome
- Pfizer Launches Independent Biotherapeutics and Bioinnovation Center
- Boehringer Ingelheim comments the nevirapine production for Rwanda by Apotex